skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy

Abstract

Purpose: Postmastectomy radiotherapy (PMRT) improves locoregional control (LRC) in patients with high-risk features after mastectomy. Young age continues to evolve as a potentially important risk factor. The objective of this study was to assess the benefits of PMRT in patients <35 years old treated with doxorubicin-based neoadjuvant chemotherapy for Stage II-III breast cancer. Patients and Methods: We retrospectively analyzed 107 consecutive breast cancer patients <35 years old with Stage IIA-IIIC disease treated at our institution with doxorubicin-based neoadjuvant chemotherapy and mastectomy, with or without PMRT. The treatment groups were compared in terms of LRC and overall survival. Results: Despite more advanced disease stages, the patients who received PMRT (n = 80) had greater rates of LRC (5-year rate, 88% vs. 63%, p = 0.001) and better overall survival (5-year rate, 67% vs. 48%, p = 0.03) than patients who did not receive PMRT (n = 27). Conclusion: Among breast cancer patients <35 years old at diagnosis, the use of PMRT after doxorubicin-based neoadjuvant chemotherapy and mastectomy led to a statistically greater rate of LRC and overall survival compared with patients without PMRT. The benefit seen for PMRT in young patients provides valuable data to better tailor adjuvant, age-specific treatment decisionsmore » after mastectomy.« less

Authors:
 [1];  [2]; ; ; ; ; ; ;  [1];  [3];  [4];  [1]
  1. Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
  2. Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States), E-mail: joh@mdanderson.org
  3. Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
  4. Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
Publication Date:
OSTI Identifier:
21039671
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 69; Journal Issue: 5; Other Information: DOI: 10.1016/j.ijrobp.2007.05.029; PII: S0360-3016(07)00944-3; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CARCINOMAS; CHEMOTHERAPY; DIAGNOSIS; DOXORUBICIN; HEALTH HAZARDS; MAMMARY GLANDS; PATIENTS; RADIOTHERAPY

Citation Formats

Garg, Amit K., Oh, Julia L., Oswald, Mary Jane, Huang, Eugene, Strom, Eric A., Perkins, George H., Woodward, Wendy A., Yu, T. Kuan, Tereffe, Welela, Meric-Bernstam, Funda, Hahn, Karin, and Buchholz, Thomas A. Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy. United States: N. p., 2007. Web. doi:10.1016/j.ijrobp.2007.05.029.
Garg, Amit K., Oh, Julia L., Oswald, Mary Jane, Huang, Eugene, Strom, Eric A., Perkins, George H., Woodward, Wendy A., Yu, T. Kuan, Tereffe, Welela, Meric-Bernstam, Funda, Hahn, Karin, & Buchholz, Thomas A. Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy. United States. doi:10.1016/j.ijrobp.2007.05.029.
Garg, Amit K., Oh, Julia L., Oswald, Mary Jane, Huang, Eugene, Strom, Eric A., Perkins, George H., Woodward, Wendy A., Yu, T. Kuan, Tereffe, Welela, Meric-Bernstam, Funda, Hahn, Karin, and Buchholz, Thomas A. Sat . "Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy". United States. doi:10.1016/j.ijrobp.2007.05.029.
@article{osti_21039671,
title = {Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy},
author = {Garg, Amit K. and Oh, Julia L. and Oswald, Mary Jane and Huang, Eugene and Strom, Eric A. and Perkins, George H. and Woodward, Wendy A. and Yu, T. Kuan and Tereffe, Welela and Meric-Bernstam, Funda and Hahn, Karin and Buchholz, Thomas A.},
abstractNote = {Purpose: Postmastectomy radiotherapy (PMRT) improves locoregional control (LRC) in patients with high-risk features after mastectomy. Young age continues to evolve as a potentially important risk factor. The objective of this study was to assess the benefits of PMRT in patients <35 years old treated with doxorubicin-based neoadjuvant chemotherapy for Stage II-III breast cancer. Patients and Methods: We retrospectively analyzed 107 consecutive breast cancer patients <35 years old with Stage IIA-IIIC disease treated at our institution with doxorubicin-based neoadjuvant chemotherapy and mastectomy, with or without PMRT. The treatment groups were compared in terms of LRC and overall survival. Results: Despite more advanced disease stages, the patients who received PMRT (n = 80) had greater rates of LRC (5-year rate, 88% vs. 63%, p = 0.001) and better overall survival (5-year rate, 67% vs. 48%, p = 0.03) than patients who did not receive PMRT (n = 27). Conclusion: Among breast cancer patients <35 years old at diagnosis, the use of PMRT after doxorubicin-based neoadjuvant chemotherapy and mastectomy led to a statistically greater rate of LRC and overall survival compared with patients without PMRT. The benefit seen for PMRT in young patients provides valuable data to better tailor adjuvant, age-specific treatment decisions after mastectomy.},
doi = {10.1016/j.ijrobp.2007.05.029},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 5,
volume = 69,
place = {United States},
year = {2007},
month = {12}
}